Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.

Wells Fargo analyst Derek Archila maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...

Small- and mid-cap stocks are poised to surpass large caps atop markets. BMO's strategy chief shared 17 stocks to buy during ...

Distinct immune "signatures" in patients who develop adverse events while taking immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side ...

Paige Mahaney, Ph.D. Chief Scientific Officer Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience ...

The valuation backdrop for small- and mid-caps continue to look compelling for investors looking to add exposure, said BMO Capital Markets' Brian G. Belski.

Merck (NYSE:MRK) announced Thursday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent ...